CJC-1295 DAC vs CJC-1295 No DAC: GHRH Analog Comparison

Introduction#

CJC-1295 DAC and CJC-1295 without DAC (Mod GRF 1-29) are two forms of the same GHRH receptor agonist that differ by a single molecular modification with dramatic pharmacokinetic consequences. The DAC (Drug Affinity Complex) moiety enables albumin binding, extending the half-life from approximately 30 minutes to 6-8 days. This single change transforms the compound from a pulsatile GH stimulator into a sustained-release GH axis activator, fundamentally altering its research applications and physiological effects.

Quick Comparison#

Mechanism of Action Comparison#

CJC-1295 DAC#

CJC-1295 DAC is a 30-amino acid synthetic analog of GHRH that incorporates the Drug Affinity Complex, a maleimido derivative of lysine that forms a covalent bond with serum albumin after subcutaneous injection. This albumin conjugation protects the peptide from DPP-IV degradation and reduces renal clearance, extending the half-life from minutes to 6-8 days.

The peptide activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, triggering Gs-cAMP-PKA signaling that stimulates both GH gene transcription and release of stored GH granules. Because receptor engagement persists for days, CJC-1295 DAC amplifies all natural GH pulses throughout the dosing interval. Somatostatin still modulates GH release, so some pulsatility is preserved, but the overall GH and IGF-1 levels are continuously elevated above baseline.

Clinical PK/PD data demonstrate dose-dependent GH increases (2-10 fold) and IGF-1 elevation (1.5-3 fold) persisting for up to 6-14 days after a single subcutaneous dose.

CJC-1295 without DAC (Mod GRF 1-29)#

CJC-1295 without DAC, commonly called Mod GRF 1-29, consists of the first 29 amino acids of human GHRH with four strategic substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer resistance to DPP-IV cleavage while preserving full GHRH-R agonist activity. Without the DAC moiety, there is no albumin binding and the peptide is cleared within approximately 30 minutes.

The mechanism at the receptor level is identical to CJC-1295 DAC: GHRH-R activation, Gs-cAMP-PKA signaling, and GH release. The critical difference is temporal. Each injection produces a discrete 1-2 hour GH pulse followed by return to baseline, closely mimicking the endogenous pattern of GHRH-stimulated pulsatile GH secretion.

This pulsatile pattern is important because GH physiology is inherently pulsatile. The amplitude and frequency of GH pulses, not just mean GH levels, influence downstream metabolic effects including hepatic IGF-1 production, lipolysis, and protein synthesis. Mod GRF 1-29 also shows strong synergy with ghrelin-mimetic peptides (ipamorelin, GHRP-6) when co-administered, as GHRH and ghrelin act through complementary pathways on somatotrophs.

Evidence and Research Comparison#

CJC-1295 DAC Research#

CJC-1295 DAC has the stronger clinical evidence base of the two. ConjuChem Biotechnologies conducted Phase 1 and Phase 2 clinical trials that demonstrated:

• Dose-dependent PK/PD: Single subcutaneous doses produced sustained, dose-proportional GH and IGF-1 elevation published in the Journal of Clinical Endocrinology and Metabolism
• Weekly dosing feasibility: Multiple weekly doses over 4-8 weeks showed progressive IGF-1 elevation without tachyphylaxis
• Safety: Generally well-tolerated at doses up to 120 mcg/kg
• Development status: The clinical program was discontinued before Phase 3 completion; the compound did not proceed to FDA approval

CJC-1295 without DAC Research#

Mod GRF 1-29 does not have an independent clinical development program. Its evidence base derives from:

• Structure-activity studies: The four amino acid modifications were characterized in research demonstrating improved metabolic stability with preserved receptor activity
• GHRH analog literature: Extensive research on native GRF(1-29) (sermorelin, which had prior FDA approval) provides pharmacological context for the modified sequence
• Combination studies: Preclinical and observational data on synergistic GH release when combined with ghrelin-mimetic peptides
• Research status: Remains at preclinical status with no independent regulatory filings

Side Effects and Safety Comparison#

CJC-1295 DAC Side Effects#

• Injection site reactions: Redness and swelling reported in clinical trials
• Sustained GH/IGF-1 elevation risks: Insulin resistance, fluid retention, joint pain, carpal tunnel-like symptoms are theoretical with chronic use
• Irreversibility: The 6-8 day half-life means any adverse effects persist for days to weeks after discontinuation
• Cancer consideration: Sustained IGF-1 elevation carries theoretical concern for cell proliferation; contraindicated with active malignancy

CJC-1295 without DAC Side Effects#

• Injection site reactions: Similar to DAC form but more frequent due to multiple daily injections
• Transient effects: Any GH-related side effects resolve within hours as the peptide clears
• Rapid reversibility: Short half-life provides inherent safety advantage; stopping the compound produces rapid return to baseline
• Lower sustained exposure: Less theoretical concern for chronic IGF-1-related risks due to intermittent rather than continuous elevation

Dosing and Administration Comparison#

CJC-1295 DAC Dosing#

CJC-1295 without DAC Dosing#

Use Case Recommendations#

Choose CJC-1295 DAC When:#

• Dosing convenience is a priority and weekly injection is preferred over multiple daily doses
• Sustained IGF-1 elevation is the research goal rather than pulsatile GH release
• Clinical-grade evidence is important, as Phase 1-2 PK/PD data are available
• Standalone use without GHRP combination is planned

Choose CJC-1295 without DAC When:#

• Physiological GH pulsatility is the goal, mimicking natural GHRH signaling
• Combination protocols with ipamorelin or GHRP-6 are planned, where temporal synchronization matters
• Safety reversibility is prioritized, with rapid clearance if adverse effects occur
• Pulsatile signaling research rather than sustained axis stimulation is the focus

Can They Be Combined?#

Combining CJC-1295 DAC with CJC-1295 without DAC is pharmacologically redundant, as both activate the same GHRH receptor. The DAC form already provides continuous receptor stimulation, making additional pulsatile GHRH agonism unlikely to add benefit. This combination is not studied and not recommended.

The more relevant combination question is CJC-1295 without DAC combined with a ghrelin-mimetic peptide like ipamorelin. GHRH and ghrelin act through complementary receptors (GHRH-R and GHS-R1a) on somatotrophs, producing synergistic GH release that exceeds the effect of either compound alone. This combination is widely used in research settings. CJC-1295 DAC can also theoretically be combined with GHRPs, but the sustained nature of DAC-mediated signaling makes precise timing coordination less meaningful.

For related GHRH analog comparisons, see our profiles on sermorelin and our sermorelin vs tesamorelin comparison.

Verdict#

CJC-1295 DAC and CJC-1295 without DAC represent the same pharmacological tool with different pharmacokinetic delivery. CJC-1295 DAC offers convenience and sustained GH/IGF-1 elevation backed by Phase 1-2 clinical data, but sacrifices physiological pulsatility and carries irreversibility risk from its long half-life. Mod GRF 1-29 preserves the natural pulsatile GH pattern and offers rapid safety reversibility, but requires multiple daily injections and has weaker clinical evidence.

Neither compound has been FDA-approved. Both are prohibited by WADA. The choice between them reflects a fundamental pharmacological trade-off between sustained convenience and physiological fidelity. Explore our half-life comparison tool to visualize how these half-life differences affect dosing schedules.

Further Reading#

• CJC-1295 DAC Overview and Research Guide
• CJC-1295 DAC Side Effects
• CJC-1295 DAC Dosing Protocols
• CJC-1295 without DAC Overview and Research Guide
• CJC-1295 without DAC Side Effects
• CJC-1295 without DAC Dosing Protocols